Biblio
[(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Mol Ther. 2015.
Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014.
Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation. J Clin Oncol. 2021:JCO2001587.
. Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma. Blood Adv. 2023.
Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl. Biol Blood Marrow Transplant. 2018.
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leuk Res. 2021;110:106713.
Hematopoietic Stem Cell Mobilization for Allogeneic Stem Cell Transplantation by Motixafortide, a Novel CXCR4 Inhibitor. Blood Adv. 2023.
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med. 2018.
Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. Blood Adv. 2021.
Mutation Clearance after Transplantation for Myelodysplastic Syndrome. N Engl J Med. 2018;379(11):1028-1041.
Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model. Molecules. 2024;29(8).
. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2015.
. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies. Blood. 2024.
Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. Leuk Res. 2018;72:86-91.
. Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation. PLoS One. 2018;13(11):e0207609.
.